Clinical Research Directory

Inclusion Criteria: * Age \>18 years * Histologically or cytologically confirmed advanced or metastatic solid tumor refractory to standard therapy * EpCAM expression ≥2+ intensity in ≥50% of tumor cells by central IHC * At least one measurable lesion per RECIST v1.1 (≥2 cm) that is anatomically accessible for intratumoral injection * ECOG performance status 0-1 * Life expectancy ≥3 months * Adequate hematologic, hepatic, renal, and coagulation function * Willingness to use effective contraception Exclusion Criteria: * Prior EpCAM- or CD3-targeted therapy * Active autoimmune disease requiring systemic therapy * Uncontrolled infection or significant cardiovascular disease * Active or symptomatic CNS metastases requiring immediate local therapy. Patients with treated, stable CNS metastases may be eligible. * Ongoing ≥Grade 2 toxicity from prior anticancer therapy * Known hypersensitivity to study drug components * Pregnancy or breastfeeding